Overview

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Status:
Terminated
Trial end date:
2019-07-03
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
Phase:
Phase 3
Details
Lead Sponsor:
Naurex, Inc, an affiliate of Allergan plc